Osteoclast targeting delivery system based on small nucleic acid medicine and preparation method of osteoclast targeting delivery system
A technology of small nucleic acid drugs and osteoclasts, which is used in drug combinations, pharmaceutical formulations, gene therapy and other directions to achieve the effects of strong specificity, high affinity and easy absorption
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0049] An embodiment of the osteoclast targeted delivery system based on small nucleic acid drugs of the present invention, the osteoclast targeted delivery system based on small nucleic acid drugs in this embodiment includes liposomes and eight gates with thiol-modified ends Aspartic acid polypeptide repeat sequence ((D-Asp8)-SH) and the blocking agent miR-148a antagomir of microribonucleic acid; Wherein, liposome is made up of the lipid of following mass percentage: distearoylphosphatidylethanolamine- Polyethylene glycol 2000-maleimide (DSPE-PEG-MAL) 5%, 1,2-dioleyloxy-3-trimethylaminopropane (DOTAP) 15%, DC-cholesterol (DC-Chol) 50%, dioleoylphosphatidylethanolamine (DOPE) 15% and distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000) 15%. In the targeted delivery system of this embodiment, the molar ratio of (D-Asp8)-SH to liposomes is 2: 100, and the mass ratio of microRNA blocking agent miR-148a antagomir to liposomes is 10%, The encapsulation effici...
Embodiment 2
[0056] An embodiment of the small nucleic acid drug-based osteoclast targeted delivery system of the present invention, the small nucleic acid drug-based osteoclast targeted delivery system in this embodiment includes liposomes and eight gates with thiol-modified ends Blocker of aspartic acid polypeptide repeat ((D-Asp8)-SH) and microRNA. Wherein, liposome is made up of the lipid of following mass percentage: dioleoyl dimethyl ammonium propane (DODAP) 10%, dioleoyl phosphatidylethanolamine (DOPE) 10%, distearoyl phosphatidyl choline (DSPC) ) 15%, DC-cholesterol (DC-Chol) 60% and distearoylphosphatidylethanolamine-polyethylene glycol 2000-maleimide (DSPE-PEG-MAL) 5%; microRNA blocking The agent is composed of miR-29a, miR-29b and miR-29c, and the mass percentages of miR-29a, miR-29b and miR-29c are 30%, 30% and 40% respectively. In the targeted delivery system of the present embodiment, the molar ratio of (D-Asp8)-SH to liposome is 10:100, the mass ratio of microRNA blocking a...
Embodiment 3
[0063] An embodiment of the small nucleic acid drug-based osteoclast targeted delivery system of the present invention, the small nucleic acid drug-based osteoclast targeted delivery system in this embodiment includes liposomes and eight gates with thiol-modified ends Blocker of aspartic acid polypeptide repeat ((D-Asp8)-SH) and microRNA. Wherein, liposome is made up of the lipid of following mass percent: 1,2-dioleyloxy-3-trimethylaminopropane (DOTAP) 5%, N-[1-(2,3-dioleyloxy) Propyl]-N,N,N,-trimethylammonium chloride (DOTMA) 10%, phosphatidylcholine (PC) 50%, DC-cholesterol (DC-Chol) 30% and distearoylphosphatidylethanolamine- Polyethylene glycol 2000-maleimide (DSPE-PEG-MAL) 5%; the microRNA blocking agent is composed of antagomir-214 and antagomir-2861 with mass percentages of 50% and 50%, respectively. In the targeted delivery system of the present embodiment, the molar ratio of (D-Asp8)-SH to liposome is 5:100, the mass ratio of microRNA blocking agent to liposome is 20...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com